Trial · NCT05210582
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
NCT05210582, Phase 2, Unknown, Clinuvel, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face. Trials, record NCT05210582. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05210582
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
- NCT number
- NCT05210582
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 6 participants, estimated
- Lead sponsor
- Clinuvel, Inc.
- Conditions
- Vitiligo
- Interventions
- Afamelanotide
- First posted
- 2022-01-27
- Last updated
- 2023-02-09
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on facial lesions | From Baseline to Day 84 | Measured using Vitiligo Area Scoring Index (VASI). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100) |
| Secondary | Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on body surface area | From Baseline to Day 84 | Proportion of participants achieving VASI25 on body surface area (excluding hands and feet). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100). |
| Secondary | Percentage change in pigmentation on body surface area measured by the VASI scoring system | From Baseline to Day 84 | Percentage change in pigmentation on body surface area (excluding hands and feet) measured by VASI scoring system. A decrease in VASI indicates a reduction of the body surface area affected by vitiligo (possible range 1-100) |
| Secondary | Percentage change in pigmentation on facial surface area measured by the VASI scoring system | From Baseline to Day 168 | A decreased VASI indicates a reduction in the faces' degree of depigmentation (possible range 1-100) |
| Secondary | Change in Perception of Vitiligo Severity using a vitiligo validated specific tool (A) | From Baseline to Day 168 | The higher the score, the more severe the disease |
| Secondary | Change in Noticeability of Vitiligo using a vitiligo validated specific tool (B) | From Baseline to Day 168 | Higher the value means lower noticeability |
| Secondary | Change in Quality of life using a vitiligo specific tool (C) | From Baseline to Day 168 | Higher value means a lower quality of life |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05210582
GET https://conductscience.org/api/trials/v1/NCT05210582/registered